NCT02993926View on ClinicalTrials.gov

A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants

CompletedOBSERVATIONAL
Enrollment

108

Participants

Timeline

Start Date

June 24, 2017

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions
Central Precocious Puberty
Interventions
DRUG

Enantone

Enantone suspension for injection

DRUG

GnRH agonist

A non-Enantone GnRH agonist

Trial Locations (6)

200040

Children's Hospital of Shanghai, Shanghai

210036

Jiangsu Province Hosptial, Nanjing

310053

The Children's Hospital, Zhejiang University School of Medicine, Hangzhou

330006

Children's Hospital of Jiangxi province, Nanchang

410007

Childrens Hospital of Hunan province, Changsha

430030

The Children's Hospital, Zhejiang University School of Medicine, Wuhan

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY